Common Raven Impacts on Nesting Western Snowy Plovers: Integrating Management to Facilitate Species Recovery

The U.S. Pacific coast population of the western snowy plover (Charadrius nivosus nivosus; plover) has declined due to loss and degradation of coastal habitats, predation, and anthropogenic disturbance. The U.S. Fish and Wildlife Service listed the subspecies in 1993 as threatened under the Endangered Species Act due to the population declines and habitat loss. Predation of nests and chicks has been identified as an important cause of historic population declines, and thus, most predator management actions for this subspecies are focused on reducing this pressure. In recent years, common ravens (Corvus corax; ravens) have become the most common and pervasive predators of plover nests and chicks, especially in areas with subsidized food sources for ravens and sites without predator management. We compiled data from a variety of sources to document the impact of raven predation on plover nesting success. We discuss current raven management and suggest several tools and strategies to increase plover nesting success, including multi-state approval for the use of the avicide DRC-1339, the use of lures and new trap types, and an increase in funding for predator management. The lack of coordinated and integrated management continues to impede the recovery of the Pacific coast plover population

Niraparib maintenance treatment improves time without symptoms or toxicity (TWiST) versus routine surveillance in recurrent ovarian cancer: a TWiST analysis of the ENGOT-OV16/NOVA trial

Purpose: this study estimated time without symptoms or toxicity (TWiST) with niraparib compared with routine surveillance (RS) in the maintenance treatment of patients with recurrent ovarian cancer. Patients and methods: mean progression-free survival (PFS) was estimated for niraparib and RS by fitting parametric survival distributions to Kaplan-Meier data for 553 patients with recurrent ovarian cancer who were enrolled in the phase III ENGOT-OV16/NOVA trial. Patients were categorized according to the presence or absence of a germline BRCA mutation-gBRCAmut and non-gBRCAmut cohorts. Mean time with toxicity was estimated based on the area under the Kaplan-Meier curve for symptomatic grade 2 or greater fatigue, nausea, and vomiting adverse events (AEs). Time with toxicity was the number of days a patient experienced an AE post-random assignment and before disease progression. TWiST was estimated as the difference between mean PFS and time with toxicity. Uncertainty was explored using alternative PFS estimates and considering all symptomatic grade 2 or greater AEs. Results: in the gBRCAmut and non-gBRCAmut cohorts, niraparib treatment resulted in a mean PFS benefit of 3.23 years and 1.44 years, respectively, and a mean time with toxicity of 0.28 years and 0.10 years, respectively, compared with RS. Hence, niraparib treatment resulted in a mean TWiST benefit of 2.95 years and 1.34 years, respectively, compared with RS, which is equivalent to more than four-fold and two-fold increases in mean TWiST between niraparib and RS in the gBRCAmut and non-gBRCAmut cohorts, respectively. This TWiST benefit was consistent across all sensitivity analyses, including modeling PFS over 5-, 10-, and 15-year time horizons. Conclusion: patients who were treated with niraparib compared with RS experienced increased mean TWiST. Thus, patients who were treated with niraparib in the ENGOT-OV16/NOVA trial experienced more time without symptoms or symptomatic toxicities compared with control

Southern Ocean Action Plan (2021-2030) in support of the United Nations Decade of Ocean Science for Sustainable Development

In 2017, the United Nations proclaimed a Decade of Ocean Science for Sustainable Development (hereafter referred to as the UN Ocean Decade) from 2021 until 2030 to support efforts to reverse the cycle of decline in ocean health. To achieve this ambitious goal, this initiative aims to gather ocean stakeholders worldwide behind a common framework that will ensure ocean science can fully support countries in creating improved conditions for sustainable development of the world’s oceans. The initiative strives to strengthen the international cooperation needed to develop the scientific research and innovative technologies that can connect ocean science with the needs of society at the global scale. Based on the recommendations in the Implementation Plan of the United Nations Decade of Ocean Science for Sustainable Development (Version 2.0, July 2021), the Southern Ocean community engaged in a stakeholder - oriented process to develop the Southern Ocean Action Plan. The Southern Ocean process engaged a broad community, which includes the scientific research community, the business and industry sector, and governance and management bodies. As part of this global effort, the Southern Ocean Task Force identified the needs of the Southern Ocean community to address the challenges related to the unique environmental characteristics and governance structure of the Southern Ocean. Through this community-driven process, we identified synergies within the Southern Ocean community and beyond in order to elaborate an Action Plan that provides a framework for Southern Ocean stakeholders to formulate and develop tangible actions and deliverables that support the UN Ocean Decade vision. Through the publication of this Action Plan, the Southern Ocean Task Force aims to mobilise the Southern Ocean community and inspire all stakeholders to seek engagement and leverage opportunities to deliver innovative solutions that maintain and foster the unique conditions of the Southern Ocean. This framework provides an initial roadmap to strengthen links between science, industry and policy, as well as to encourage internationally collaborative activities in order to address existing gaps in our knowledge and data coverage

Alfabetización mediática y co-innovación en la microempresa: primeras evidencias para España

Media literacy and co-innovation in microenterprises: first evidence in Spain.- The inexorable progress of ICT has brought about radical changes in the social and business world. In this context, new pat-terns of communication and participation, especially since the advent of Web 2.0, and the widespread use of smartphones by the whole population, are particularly striking. In this situation, it is essential to establish what kind of personal skills related to the efficient use of media can be useful from a business perspective, and how these media literacy skills can be aligned with other factors, such as innovation, that determine the competitiveness of companies. In this paper, we analyze the media skills of workers and their connections to the innovation processes in microenterprises. With this analytical objective, exploratory fieldwork has been done in a sample of 154 professionals working in Spanish microenterprises

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial

PURPOSE Immunotherapy and chemotherapy combinations have shown activity in endometrial cancer, with greater benefit in mismatch repair (MMR)-deficient (dMMR) than MMR-proficient (pMMR) disease. Adding a poly(ADP-ribose) polymerase inhibitor may improve outcomes, especially in pMMR disease. METHODS This phase III, global, double-blind, placebo-controlled trial randomly assigned eligible patients with newly diagnosed advanced or recurrent endometrial cancer 1:1:1 to: carboplatin/paclitaxel plus durvalumab placebo followed by placebo maintenance (control arm); carboplatin/paclitaxel plus durvalumab followed by maintenance durvalumab plus olaparib placebo (durvalumab arm); or carboplatin/paclitaxel plus durvalumab followed by maintenance durvalumab plus olaparib (durvalumab + olaparib arm). The primary end points were progression-free survival (PFS) in the durvalumab arm versus control and the durvalumab + olaparib arm versus control. RESULTS Seven hundred eighteen patients were randomly assigned. In the intention-to-treat population, statistically significant PFS benefit was observed in the durvalumab (hazard ratio [HR], 0.71 [95% CI, 0.57 to 0.89]; P = .003) and durvalumab + olaparib arms (HR, 0.55 [95% CI, 0.43 to 0.69]; P < .0001) versus control. Prespecified, exploratory subgroup analyses showed PFS benefit in dMMR (HR [durvalumab v control], 0.42 [95% CI, 0.22 to 0.80]; HR [durvalumab + olaparib v control], 0.41 [95% CI, 0.21 to 0.75]) and pMMR subgroups (HR [durvalumab v control], 0.77 [95% CI, 0.60 to 0.97]; HR [durvalumab + olaparib v control] 0.57; [95% CI, 0.44 to 0.73]); and in PD-L1-positive subgroups (HR [durvalumab v control], 0.63 [95% CI, 0.48 to 0.83]; HR [durvalumab + olaparib v control], 0.42 [95% CI, 0.31 to 0.57]). Interim overall survival results (maturity approximately 28%) were supportive of the primary outcomes (durvalumab v control: HR, 0.77 [95% CI, 0.56 to 1.07]; P = .120; durvalumab + olaparib v control: HR, 0.59 [95% CI, 0.42 to 0.83]; P = .003). The safety profiles of the experimental arms were generally consistent with individual agents. CONCLUSION Carboplatin/paclitaxel plus durvalumab followed by maintenance durvalumab with or without olaparib demonstrated a statistically significant and clinically meaningful PFS benefit in patients with advanced or recurrent endometrial cancer

Reichweitensprung auf über 500 Kilometer möglich

<p>(a) Scatter plot showing breast volume against contact area (N = 15818). (b) Box plot showing breast volume for the left CC (n = 3897), left MLO (n = 3954), right CC (n = 3960) and right MLO views (n = 4007).</p

Mammographic compression in Asian women

<div><p>Objectives</p><p>To investigate: (1) the variability of mammographic compression parameters amongst Asian women; and (2) the effects of reducing compression force on image quality and mean glandular dose (MGD) in Asian women based on phantom study.</p><p>Methods</p><p>We retrospectively collected 15818 raw digital mammograms from 3772 Asian women aged 35–80 years who underwent screening or diagnostic mammography between Jan 2012 and Dec 2014 at our center. The mammograms were processed using a volumetric breast density (VBD) measurement software (Volpara) to assess compression force, compression pressure, compressed breast thickness (CBT), breast volume, VBD and MGD against breast contact area. The effects of reducing compression force on image quality and MGD were also evaluated based on measurement obtained from 105 Asian women, as well as using the RMI156 Mammographic Accreditation Phantom and polymethyl methacrylate (PMMA) slabs.</p><p>Results</p><p>Compression force, compression pressure, CBT, breast volume, VBD and MGD correlated significantly with breast contact area (p<0.0001). Compression parameters including compression force, compression pressure, CBT and breast contact area were widely variable between [relative standard deviation (RSD)≥21.0%] and within (p<0.0001) Asian women. The median compression force should be about 8.1 daN compared to the current 12.0 daN. Decreasing compression force from 12.0 daN to 9.0 daN increased CBT by 3.3±1.4 mm, MGD by 6.2–11.0%, and caused no significant effects on image quality (p>0.05).</p><p>Conclusions</p><p>Force-standardized protocol led to widely variable compression parameters in Asian women. Based on phantom study, it is feasible to reduce compression force up to 32.5% with minimal effects on image quality and MGD.</p></div

Summary of compressed breast thicknesses of the women according to the mammographic view, age group and BI-RADS density category.

<p>Summary of compressed breast thicknesses of the women according to the mammographic view, age group and BI-RADS density category.</p

Weighted kappa value for the agreement of image quality assessment between the four observers based on all their fiber, mass, calcification and total scores when the RMI156 phantom was exposed both with and without 5 mm of PMMA slabs added for W/Ag at 30 kVp.

<p>Weighted kappa value for the agreement of image quality assessment between the four observers based on all their fiber, mass, calcification and total scores when the RMI156 phantom was exposed both with and without 5 mm of PMMA slabs added for W/Ag at 30 kVp.</p